Overview

• Seres Therapeutics reports Q3 net income of $8.2 mln, reversing a loss from last year

• Company reduces operating expenses through cost-reduction measures, including workforce reductions

• Seres finalizing SER-155 Phase 2 study protocol, interim results expected within 12 months

• Seres receives $3.6 mln CARB-X grant for SER-155 development

Outlook

• Seres expects interim results from SER-155 Phase 2 study within 12 months of initiation

• Company anticipates initial results from immune checkpoint enterocolitis study in early 2026

• Seres expects to fund operations through Q2 2026

Result Drivers

• COST REDUCTION - Seres implemented cost-reduction measures, including workforce reductions, to fund operations through Q2 2026

• CARB-X GRANT - Seres received a $3.6 mln grant from CARB-X to support the development of an oral liquid formulation of SER-155

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Seres Therapeutics Inc is $20.00, about 31.3% above its November 4 closing price of $13.75

Press Release: ID:nGNX2g2PnC

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)